Abivax Shares Surge 2.9% on 290% Volume Spike Ranks 393rd as FDA Grants Conditional Phase III Approval with Mid-2026 Safety Deadline

, . The biotech firm’s shares saw renewed institutional interest following a regulatory update regarding its Phase II clinical trial for a novel antiviral candidate. The U.S. Food and Drug Administration () granted a conditional approval to advance the trial to Phase III, contingent on additional safety data submission by mid-2026. This development, though not immediately altering the drug’s timeline, reduced short-term selling pressure from hedge funds previously hedging against regulatory risks.

Analysts noted that the volume spike correlated with a broader sector rotation into , driven by renewed optimism around . , including an upcoming investor presentation scheduled for October 15. , signaling potential for further gains if the R&D pipeline remains on track.

At the moment, the built-in back-test engine you and I can invoke is designed to evaluate a single security (one ticker) at a time. Your requested strategy—re-ranking the entire stock universe every day, buying the 500 highest-volume names, and holding them for one day—requires (1) daily cross-sectional ranking of many tickers, and (2) portfolio-level return aggregation. Those two steps fall outside the current capability of the single-ticker back-test engine exposed to me.